The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial

    loading  Checking for direct PDF access through Ovid



Being female is an independent predictor of adverse events during percutaneous coronary interventions (PCI).


To evaluate the safety and efficiency of bivalirudin during emergency PCI in female patients with acute myocardial infarction (AMI).


The present study was a subgroup analysis of the randomized Bivalirudin in Acute Myocardial Infarction vs. Heparin and GPI plus Heparin (BRIGHT) trial. A total of 392 female patients enrolled in the BRIGHT trial were assigned to receive bivalirudin with post-procedure dose infusion (n= 127) or heparin with or without tirofiban (n= 265). The primary efficiency endpoint was 30-day net adverse clinical events (NACEs). The secondary efficiency endpoints were 30-day major cardiac and cerebral events (MACCEs) and bleeding events defined according to Bleeding Academic Research Consortium (BARC) definitions.


For female patients, bivalirudin treatment was associated with significantly lower incidences of 30-day NACEs (6.3% vs. 21.5%,P< 0.001), any bleeding (2.4% vs. 12.8%,P= 0.001) and BARC 2–5 type bleeding (1.6% vs. 7.2%,P= 0.021) compared with the control regimen. The incidence of MACCEs (3.4% vs. 9.4%,P= 0.055) and stent thrombosis (0% vs. 1.1%,P= 0.229) were comparable between the two groups. Multivariate analysis showed that bivalirudin (OR: 0.245, 95% CI: 0.113–0.532,P< 0.001), transradial access (OR: 0.119, 95% CI: 0.067–0.211,P< 0.001), and statin (OR: 0.254, 95% CI: 0.08–0.807,P= 0.02) were independent protective factors for 30-day NACEs in female patients.


The use of bivalirudin during emergency PCI for AMI in female patients significantly reduced the bleeding risk with anticoagulation effects compared with heparin with or without tirofiban. © 2016 Wiley Periodicals, Inc.

Related Topics

    loading  Loading Related Articles